Kintara Therapeutics, Inc , a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients.
infoKintara Therapeutics is a micro cap stock with a total market cap of 6.16M.
infoThey trade on the NASDAQ and had their IPO 10 years and 6 months ago.
infoKintara Therapeutics currently employs 3 people.
infoAs of Wednesday, Aug 23 2023, Kintara Therapeutics’s share price is $3.64.
News Relating to Kintara Therapeutics
PRNewsWire
Kintara Therapeutics to Present at the Emerging Growth Conference
Wednesday Aug 09 2023 at 08:16
SAN DIEGO , Aug. 9, 2023 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its President and CEO, Robert E. Hoffman will present in the Emerging Growth Conference on Wednesday, August 9, 2023 at 12:00 pm ET.
Zacks Investment Research
Kintara (KTRA) Rises 41% on $2M Grant for Breast Cancer Therapy
Friday Jun 30 2023 at 12:12
Kintara (KTRA) receives a $2 million grant from the National Institutes of Health to develop its breast cancer treatment candidate, REM-001. The stock surges 41%.
PRNewsWire
Kintara Therapeutics Scheduled to Present at Two Conferences the Week of March 13, 2023
Friday Mar 10 2023 at 08:30
-35th Annual ROTH Conference, March 12-14, 2023 – -4th Annual Glioblastoma Drug Development Summit, March 14-16, 2023- SAN DIEGO , March 10, 2023 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announces its participation in two upcoming conferences. 35th Annual ROTH Conference, March 12-14, 2023 – Dana Point, CA Mr.
MarketBeat
Is Kintara Therapeutics A Hidden Gem?
Friday Dec 30 2022 at 01:01
Kintara Therapeutics’ earnings are in the red but impressive FDA approvals could satisfy an extreme upside potential to bring them solvent by next year.
Benzinga
Why Kintara Therapeutics Stock Is Seeing Blue Skies Thursday – Kintara Therapeutics (NASDAQ:KTRA)
Thursday Dec 15 2022 at 11:49
Kintara Therapeutics Inc KTRA shares are trading higher by 24.09% to $9.94 Thursday morning after the company received FDA Orphan Drug Designation (ODD) for VAL-083.
PennyStocks
3 Strategies for Buying and Selling Penny Stocks Right Now
Thursday Oct 20 2022 at 06:00
Can these penny stocks trading tips help your strategy? The post 3 Strategies for Buying and Selling Penny Stocks Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PRNewsWire
Kintara Therapeutics to Present at the Alliance Global Partners Summer Healthcare Conference
Tuesday Jun 21 2022 at 08:00
SAN DIEGO , June 21, 2022 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that President and CEO Robert E. Hoffman will present a corporate overview at the Alliance Global Partners Summer Healthcare Conference.
Benzinga
Why Kintara Therapeutics Shares Are Skyrocketing Today
Wednesday Jun 15 2022 at 11:55
Kintara Therapeutics Inc (NASDAQ: KTRA) shares are trading higher by 28.6% to $0.24 after the FDA granted Fast Track Designation to the company’s VAL-083. Fast Track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an.
PennyStocks
3 Red Hot Penny Stocks Under $1 To Watch Before Next Week
Wednesday Jun 15 2022 at 10:58
There are over 500 Nasdaq & NYSE listed stocks, right, and warrants… The post 3 Red Hot Penny Stocks Under $1 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks
Best Tips for Buying Penny Stocks in 2022? 3 to Know
Sunday Jun 12 2022 at 17:00
Here’s what you need to know about buying penny stocks in 2022 The post Best Tips for Buying Penny Stocks in 2022? 3 to Know appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
InvestorPlace
7 Penny Stocks With 10x Potential This Year
Tuesday May 17 2022 at 07:00
These penny stocks all have 10x potential or greater during the remainder of 2022. They are risky but relatively straightforward.
PennyStocks
Best Penny Stocks to Buy Today? 3 Climbing In Morning Trading
Wednesday Apr 27 2022 at 09:30
Here’s what you need to know about trading penny stocks on April 27th The post Best Penny Stocks to Buy Today? 3 Climbing In Morning Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks
Best Penny Stocks to Buy Under $2? 3 to Watch in May
Tuesday Apr 26 2022 at 17:38
Are these under $2 penny stocks on your watchlist right now? The post Best Penny Stocks to Buy Under $2?
PennyStocks
Popular Penny Stocks to Buy in April? 3 to Watch Right Now
Monday Apr 11 2022 at 17:23
Check these three penny stocks out in April 2022 The post Popular Penny Stocks to Buy in April? 3 to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Proactive Investors
Kintara Therapeutics presents data on VAL-083 at the 2022 American Association for Cancer Research Annual Meeting
Monday Apr 11 2022 at 16:17
Kintara Therapeutics (NASDAQ:KTRA) Inc presented data at the 2022 American Association for Cancer Research (AACR) Annual Meeting. The San Diego, California-based company is developing novel cancer therapies for patients with unmet medical needs, including VAL-083 for Glioblastoma Multiforme (GBM) and REM-001 for Cutaneous Metastatic Breast Cancer (CMBC).
PRNewsWire
Kintara Therapeutics to Present at BIO CEO & Investor Conference on February 15, 2022
Friday Feb 04 2022 at 07:00
SAN DIEGO, Feb. 4, 2022 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its President and Chief Executive Officer, Robert E. Hoffman will present a corporate overview at the BIO CEO & Investor Conference, which is being held on February 14 – 17, 2022 at the New York Marriott Marquis in New York City, NY.
Proactive Investors
Kintara Therapeutics announces multi-year research grant to support research of its VAL-083 program to treat glioblastoma
Wednesday Jan 12 2022 at 09:26
Kintara Therapeutics Inc has announced a multi-year research grant from Luxembourg National Research Fund (FNR) and Cancer Foundation Luxembourg to support the research of its VAL-083 program to treat glioblastoma (GBM), an aggressive brain cancer. The grant has been awarded to Dr. Anna Golebiewska, who is co-leading the NORLUX Neuro-Oncology laboratory with Professor Simone Niclou at the Luxembourg Institute of Health.
Proactive Investors
Kintara Therapeutics announces first international site activation in its Phase 2/3 clinical trial for glioblastoma multiforme
Tuesday Nov 30 2021 at 11:46
Kintara Therapeutics (NASDAQ:KTRA) Inc announced its first international site activation in its Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM). The treatment arm was activated in Canada at Toronto’s Sunnybrook Health Sciences Centre.
Proactive Investors
Kintara presents updates on two Phase 2 clinical studies at the 2021 Society for Neuro-Oncology annual meeting
Thursday Nov 18 2021 at 11:50
Kintara Therapeutics (NASDAQ:KTRA) Inc., a biopharmaceutical company focused on the development of new solid tumor cancer therapies, has revealed data from two scientific posters for its Phase 2 clinical studies of VAL-083, the company’s lead compound for the treatment of glioblastoma multiforme (GBM), a lethal brain cancer and other solid tumors. The data is being presented at the two-day 26th annual scientific meeting of the Society for Neuro-Oncology (SNO) starting on November 18, 2021, in Boston.
PRNewsWire
Kintara Therapeutics to Present at the Q4 Investor Summit Virtual Conference on November 17, 2021
Thursday Nov 11 2021 at 08:30
SAN DIEGO, Nov. 11, 2021 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announces today that its Chief Executive Officer, Robert E. Hoffman, will present a corporate overview at the Q4 Investor Summit Conference, which is being held virtually on November 16 – 17, 2021.
Proactive Investors
Kintara Therapeutics is developing innovative cancer therapies for rare, unmet medical needs
Tuesday Nov 09 2021 at 11:01
Two Phase 3-ready therapeutics Well capitalized to achieve clinical milestones Multiple US/EU Orphan Drug and Fast Track designations What Kintara Therapeutics does: Kintara Therapeutics, Inc (NASDAQ:KTRA) is developing advanced cancer therapies for patients with rare unmet medical needs. The San Diego-based company is currently developing two Phase 3-ready therapeutics: VAL-083 for treating glioblastoma (GBM), the most common and most aggressive form of primary brain cancer in adults and; REM-001 for treating cutaneous metastatic breast cancer (CMBC).
Proactive Investors
Kintara Therapeutics appoints Robert Hoffman as its new CEO
Tuesday Nov 09 2021 at 10:55
Kintara Therapeutics (NASDAQ:KTRA) Inc has announced that its chairman, Robert Hoffman, has succeeded Saiid Zarrabian as the company’s president and CEO effective November 8, 2021. Kintara said Hoffman will continue in his role as the company’s chairman, while Zarrabian will transition to lead Kintara’s strategic partnerships initiative and will remain a member of its board of directors.
PennyStocks
Hot Penny Stocks To Add to Your Watchlist Right Now
Friday Nov 05 2021 at 14:45
Which penny stocks are you watching next week? The post Hot Penny Stocks To Add to Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks
Do These Penny Stocks Present a Buying Opportunity At Current Levels?
Thursday Oct 14 2021 at 16:06
Are these penny stocks worth it at their current levels? The post Do These Penny Stocks Present a Buying Opportunity At Current Levels?
PennyStocks
Best Biotech Penny Stocks on Reddit to Buy Now? 4 For Your Watchlist
Tuesday Oct 12 2021 at 16:07
Looking for biotech penny stocks to watch on Reddit? Check these four out for your list The post Best Biotech Penny Stocks on Reddit to Buy Now?
Pulse2
KTRA Stock: Why It Increased This Week
Tuesday Oct 12 2021 at 11:28
The stock price of Kintara Therapeutics Inc (NASDAQ: KTRA) increased by over 20% this past week. This is why it happened.
Proactive Investors
Aegis Capital gives Kintara Therapeutics a ‘Buy’ rating
Friday Oct 01 2021 at 09:29
Kintara Therapeutics Inc, an oncology-focused, clinical-stage biopharmaceutical company received a ‘Buy’ rating from Aegis Capital. The analysts noted the biotech firm, which is developing VAL-083 for the treatment of glioblastoma multiforme (GBM) and REM-001 for the treatment of cutaneous metastatic breast cancer has several catalysts ahead that could lead to company growth.
Benzinga
Kintara Therapeutics: Q4 Earnings Insights
Thursday Sep 30 2021 at 07:16
Kintara Therapeutics(NASDAQ:KTRA) stock fell by 5.89% on Wednesday after the company reported its Q4 earnings results on Tuesday, September 28, 2021 at 08:00 AM. Here’s what investors need to know about the announcement.
Proactive Investors
Kintara heads into new fiscal year with strengthened balance sheet
Wednesday Sep 29 2021 at 09:53
Kintara Inc, a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reports that it closed its fiscal year on June 30 with cash and cash equivalents of about $10.5 million. In a statement, the company noted that its balance sheet as of September 28 grew even stronger as it closed on a registered direct offering, priced at-the-market under Nasdaq rules, raising about $15 million to help fund ongoing clinical studies and corporate working capital needs.
PRNewsWire
Kintara Therapeutics Announces Fiscal Year 2021 Financial Results and Provides Corporate Update
Wednesday Sep 29 2021 at 08:00
SAN DIEGO, Sept. 29, 2021 /PRNewswire/ — https://www.kintara.com/ (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal year ended June 30, 2021 and provided a corporate update.
Kintara Therapeutics Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Kintara Therapeutics’s Altman Z-score is -37.2 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Kintara Therapeutics Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in Kintara Therapeutics.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Kintara Therapeutics’s Income Quality of 0.93 is greater than its Industry Group of 0.69 (34.8% greater)
Kintara Therapeutics’s Income Quality of 0.93 is greater than its Major Industry Group of 0.71 (31.0% greater)
Kintara Therapeutics’s Income Quality of 0.93 is greater than its Sector of 0.75 (24.0% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Kintara Therapeutics’s Current Ratio of 2.16 is lower than its Industry Group of 4.76 (-54.6% lower)
Kintara Therapeutics’s Current Ratio of 2.16 is lower than its Major Industry Group of 4.32 (-50.0% lower)
Kintara Therapeutics’s Current Ratio of 2.16 is lower than its Sector of 2.6 (-16.9% lower)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-0.37 & -1.27)
Cannot compare a negative PE Ratio (-0.37 & -1.1)
Cannot compare a negative PE Ratio (-0.37 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Kintara Therapeutics’s PB Ratio of 1.63 is greater than its Industry Group of 1.34 (21.6% greater)
Kintara Therapeutics’s PB Ratio of 1.63 is greater than its Major Industry Group of 1.4 (16.4% greater)
Kintara Therapeutics’s PB Ratio of 1.63 is in line with its Sector of 1.62 (0.6% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Kintara Therapeutics’s ROE of -4.38 is lower than its Industry Group of -0.44 (-895.5% lower)
Kintara Therapeutics’s ROE of -4.38 is lower than its Major Industry Group of -0.38 (-1052.6% lower)
Kintara Therapeutics’s ROE of -4.38 is lower than its Sector of -0.03 (-14500.0% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Kintara Therapeutics’s ROCE of -4.28 is lower than its Industry Group of -0.42 (-919.0% lower)
Kintara Therapeutics’s ROCE of -4.28 is lower than its Major Industry Group of -0.37 (-1056.8% lower)
Kintara Therapeutics’s ROCE of -4.28 is lower than its Sector of -0.04 (-10600.0% lower)
Derived from SEC.GOV filing dataopen_in_new